Uncertainty in prevention of cervical cancer with the human Papillomavirus vaccine

Authors

  • Juan Gérvas Médico de Canencia de la Sierra, Garganta de los Montes y El Cuadrón (Madrid) España Equipo CESCA, Madrid, España

DOI:

https://doi.org/10.32385/rpmgf.v23i5.10404

Keywords:

Vaccines, Human Papillovirus, Evaluation

Abstract

Questions and doubt around cervical cancer prevention with the vaccine against human papillomavirus The vaccine against human papillomavirus has been marketed in 2007. It is recommended for use in children aged 11 and 12 years to prevent cervical cancer, because of the strong association of cervical cancer with the presence of some oncogenic types of papillomavirus. The vaccine is already included in the official calendar in many developed countries. In this paper the author reviews the scientific basis of that decision. Critical questions are: stability in the epidemiology of the infection and incidence and mortality of cervical cancer, lack of correlation between levels of serologic immunity and the natural one, the impact of the vaccine in virus ecology, the cost-effectiveness without a definitive answer to the duration of the vaccination, the pharmaceutical industry sponsorship of most research and the need to maintain screening with Papanicolaou. We need more time and information before establishing a vaccine population program.

Downloads

Download data is not yet available.

Downloads

Published

2007-09-01

Issue

Vol. 23 No. 5 (2007): Revista Portuguesa de Clínica Geral

Section

Opinion and Debate

License

The authors will assign to the RPMGF the sole right to publish and distribute the content of the manuscript specified in this declaration via physical, electronic, broadcasting or any other medium that may come into existence. They also grant the RPMGF the right to use and exploit this manuscript, in particular by assigning, selling or licensing its content. This permission is permanent and takes effect from the moment the manuscript is submitted, has the maximum duration allowed by applicable Portuguese or international law and is of worldwide scope. The authors further declare that this assignment is made free of charge. If the RPMGF informs the authors that it is not going to publish their manuscript, the exclusive assignment of rights ceases forthwith.

The authors authorise the RPMGF (or any entity it may appoint) to act on their behalf when it believes that copyright may have been infringed.

 

How to Cite

Uncertainty in prevention of cervical cancer with the human Papillomavirus vaccine. (2007). Portuguese Journal of Family Medicine and General Practice, 23(5), 547-55. https://doi.org/10.32385/rpmgf.v23i5.10404

Most read articles by the same author(s)